Antigen-Heterologous Vaccination Regimen Triggers Alternate Antibody Targeting in SARS-CoV-2-DNA-Vaccinated Mice.
Anders FrischeKaren Angeliki KrogfeltAnders FomsgaardRia LassaunièrePublished in: Vaccines (2024)
An in-depth analysis of antibody epitopes following vaccination with different regimens provides important insight for developing future vaccine strategies. B-cell epitopes conserved across virus variants may be ideal targets for vaccine-induced antibodies and therapeutic drugs. However, challenges lie in identifying these key antigenic regions, and directing the immune system to target them. We previously evaluated the immunogenicity of two candidate DNA vaccines encoding the unmodified spike protein of either the SARS-CoV-2 Index strain or the Beta variant of concern (VOC). As a follow-on study, we characterized here the antibody binding profiles of three groups of mice immunized with either the DNA vaccine encoding the SARS-CoV-2 Index strain spike protein only, the Beta VOC spike protein only, or a combination of both as an antigen-heterologous prime-boost regimen. The latter induced an antibody response targeting overlapping regions that were observed for the individual vaccines but with additional high levels of antibody directed against epitopes in the SD2 region and the HR2 region. These heterologous-vaccinated animals displayed improved neutralization breadth. We believe that a broad-focused vaccine regimen increases neutralization breadth, and that the in-depth analysis of B-cell epitope targeting used in this study can be applied in future vaccine research.
Keyphrases
- sars cov
- circulating tumor
- respiratory syndrome coronavirus
- cell free
- single molecule
- cancer therapy
- high glucose
- diabetic rats
- protein protein
- binding protein
- drug induced
- transcription factor
- optical coherence tomography
- current status
- amino acid
- saccharomyces cerevisiae
- gene expression
- small molecule
- drug delivery
- adipose tissue
- metabolic syndrome
- copy number